Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.


TSXV:AQS - Post by User

Bullboard Posts
Comment by stockwatch99on Apr 10, 2019 2:28am
54 Views
Post# 29605298

RE:RE:RE:RE:RE:RE:Links...interesting reading...

RE:RE:RE:RE:RE:RE:Links...interesting reading...Lol, you are very funny. After you latest rant and "all the way down" prediction, the share price was moving up 15% from Wednesday to Monday, from 0.17CAD to 0.195CAD. Where were you then? Quiet in your little corner! Now the share price drops to 0.18CAD with lower volume and you're back ranting. Transparent bashing this is called.

Furthermore, it is irrelevant what the share price is doing during the next 1-2 weeks. The important part is what happens after financing closes and AQS will start issuing a news flow with plenty of interesting news. News about revenue growth, the Trokendi study start, the new ophthalmology product, more Zepto deals, the cannabis product plans, etc.

Of course, you have no clue about all these things but hey, who in the Internet needs any knowledge when you just can have an anonymous opinion ... blah blah blah ...
Bullboard Posts